Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again) (NASDAQ:TVTX)

seekingalpha.com · 2026-08-06

Travere reported Filspari net product sales up year-on-year, with contribution from its Tiopronin products. Learn why TVTX stock is downgraded to hold.

Read the full story at seekingalpha.com →